Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

26. März 2025 04:30 ET | Quelle: Alvotech

UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully...
26. März 2025 04:30 ET | Quelle: Alvotech

UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)

REYKJAVIK, Iceland, PISCATAWAY, N.J. and LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of...
20. März 2025 03:00 ET | Quelle: Alvotech

Alvotech kaupir þróunarstarfsemi líftæknifyrirtækisins Xbrane í Svíþjóð

Alvotech (NASDAQ: ALVO) tilkynnti í dag að fyrirtækið hafi keypt þróunarstarfsemi sænska líftæknifyrirtækisins Xbrane Biopharma AB (“Xbrane”). Með kaupunum eykur Alvotech afkastagetu sína í þróun...
20. März 2025 03:00 ET | Quelle: Alvotech

Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the acquisition of Xbrane Biopharma...
20. März 2025 03:00 ET | Quelle: Alvotech

Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production

Alvotech acquires all Xbrane's operations and Cimizia biosimilar candidate, further expanding development capabilities, considers listing on Swedish market
18. März 2025 08:30 ET | Quelle: Alvotech

Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

HYDERABAD, India and REYKJAVIK, Iceland, March 18, 2025 (GLOBE NEWSWIRE) -- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries...
18. März 2025 08:30 ET | Quelle: Alvotech

Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”) and Alvotech (NASDAQ: ALVO), a global biotech...
18. März 2025 08:30 ET | Quelle: Alvotech

Matvæla- og lyfjaeftirlit Bandaríkjanna (FDA) samþykkir að taka til afgreiðslu umsókn um markaðsleyfi fyrir AVT03, fyrirhugaða hliðstæðu við Prolia og Xgeva

Alvotech (NASDAQ: ALVO) og samstarfsaðili þess, alþjóðlega lyfjafyrirtækið Dr. Reddy‘s Laboratories Ltd. („Dr. Reddy‘s“) tilkynntu í dag að Matvæla- og lyfjaeftirlit Bandaríkjanna (FDA) hafi samþykkt...
07. März 2025 09:00 ET | Quelle: Alvotech

Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida

REYKJAVIK, Iceland, March 07, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
07. März 2025 09:00 ET | Quelle: Alvotech

Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in Barclays 27th...

Vorherige Seite

Nächste Seite